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Abstract
Background: The Salmonella Gallinarum (SG) lon/cpxR deletion mutant JOL916 was developed as a live vaccine
candidate for fowl typhoid (FT), and a SG mutant secreting an Escherichia coli heat-labile enterotoxin B subunit
(LTB), designated JOL1229, was recently constructed as an adjuvant strain for oral vaccination against FT. In this
study, we evaluated the immunogenicity and protective properties of the SG mutant JOL916 and the LTB adjuvant
strain JOL1229 in order to establish a prime and boost immunization strategy for each strain. In addition, we
compared the increase in body weight, the immunogenicity, the egg production rates, and the bacteriological egg
contamination of these strains with those of SG 9R, a widely used commercial vaccine.
Results: Plasma IgG, intestinal secretory IgA (sIgA), and cell-mediated responses were significantly induced after a
boost inoculation with a mixture of JOL916 and JOL1229, and significant reductions in the mortality of chickens
challenged with a wild-type SG strain were observed in the immunized groups. There were no significant
differences in increases in body weight, cell-mediated immune responses, or systemic IgG responses between our
vaccine mixture and the SG 9R vaccine groups. However, there was a significant elevation in intestinal sIgA in
chickens immunized with our mixture at 3 weeks post-prime-immunization and at 3 weeks post-boost-immunization,
while sIgA levels in SG 9R-immunized chickens were not significantly elevated compared to the control. In addition,
the SG strain was not detected in the eggs of chickens immunized with our mixture.
Conclusion: Our results suggest that immunization with the LTB-adjuvant strain JOL1229 can significantly increase the
immune response, and provide efficient protection against FT with no side effects on body weight, egg production, or
egg contamination.
Background
Fowl typhoid (FT) is a severe septicemic bacterial dis-
ease in poultry caused by Salmonella enterica serovar
Gallinarum biovar Gallinarum (SG), which can be hori-
zontally or vertically transmitted [1,2]. Due to a variety
of factors, both the morbidity and mortality of FT are
highly variable, and a recent study reported mortality
rates in excess of 60% in experimentally infected chick-
ens [3]. Although strong eradication programs have
largely or completely controlled the disease in North
America and several European countries, SG is still of
considerable economic importance in many countries
throughout South America, Africa, and Asia [2]. Attenu-
ated rough strains of SG strain 9 (SG 9R) have been used
as live vaccines for chickens since the 1950s [4]. SG 9R
strain has been still accepted as the most effective live
vaccine against FT infection in endemic countries [5,6].
Unfortunately, invasive administration of the 9R vaccine
using syringes is both uneconomical and labor intensive.
Recently, an SG mutant, JOL916 was constructed as a
live vaccine candidate for FT by deleting the lon and
cpxR genes, which are related to the host-pathogen
interaction [7]. An attenuated SG strain, JOL1229, which
secretes Escherichia coli heat-labile enterotoxin B sub-
unit (LTB), was also constructed as an adjuvant strain
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for oral vaccination against FT [8]. A non-toxic LTB
binds to the monosialotetrahexosylganglioside (GM1)
ganglioside receptors of target cells, and induces the cell
to take up the whole toxin, which allows for the
utilization of LTB as an adjuvant for foreign antigens
[9]. LTB acts on modulating cell-mediated immune
responses (Th1) and humoral immune responses (Th2)
[10]. Oral immunization with a mixture of four parts
JOL916 and one part JOL1229 was reported to enhance
the immune response and provide efficient protection
against FT in 6-week-old chickens [8]. In order to
maintain immunogenicity till the egg laying period in
inoculated chickens, it will be necessary to optimize
this novel oral immunization strategy through a prime-
boost strategy using the LTB adjuvant strain. In the
present study, we aimed to establish prime and boost
immunization strategies using the SG mutant JOL916
and the LTB adjuvant strain JOL1229, and we examined
both the immune responses and protection efficacy. In
addition, changes in body weight, immunogenicity, egg
production rates, and bacteriological contamination after
immunization with the JOL916-JOL1229 mixture were
compared with a SG 9R-immunized group.
Methods
Experimental animals
Female Hy-Line Brown layer chickens were used in this
study. Chickens were provided with ad libitum access to
water and antibiotic-free feed. Animal experiments were
conducted with the approval of the Chonbuk National
University Animal Ethics Committee in accordance with
the guidelines of the Korean Council on Animal Care
(CBU 2011–0017).
Bacterial strains
JOL916, an SG mutant with the lon and cpxR genes de-
leted, was used as the live vaccine strain [7], and
JOL1229, which carries a recombinant Asd+ plasmid
harboring the eltB gene expressing LTB protein, was
used as the live adjuvant strain [8]. For comparative study
with a commercial SG vaccine, the Nobilis® SG9R vaccine
(Intervet International, Boxmeer, The Netherlands) was
used. The wild-type SG strain JOL420, provided by the
Animal, Plant, and Fisheries Quarantine and Inspection
Agency of Korea, was used for the challenge inoculation
to induce acute systemic FT.
Experimental design
Experiment 1: For the optimization of the prime-boost
immunization strategy using JOL1229, thirty female chick-
ens were divided into three groups (n = 10 per group).
Chickens were orally primed at 6 weeks of age and orally
boosted at 16 weeks of age. The immunization protocols
are described in Table 1. Each bird in the immunized
groups was orally inoculated with 200 μl of bacterial sus-
pension containing 1 × 108 colony-forming units (CFU),
and each chicken in the control group was given 200 μl of
phosphate-buffered saline (PBS). Group A chickens were
primed and boosted with a mixture consisting of four
parts JOL916 (0.8 × 108 CFU) and one part JOL1229 (0.2 ×
108 CFU), group B chickens were primed with a mixture
consisting of four parts JOL916 (0.8 × 108 CFU) and one
part JOL1229 (0.2 × 108 CFU), and were boosted with
JOL916, and group C chickens were inoculated with PBS
as the control group. At four weeks after boost-
immunization, hens were orally challenged with 1 × 106
CFU of the wild-type SG strain, JOL420.
Experiment 2: For the comparison of the safety and ef-
ficacy of our SG vaccine candidate with the commercial
vaccine SG 9R, thirty-six chickens were divided into
three groups. Group I chickens were orally primed and
boosted with 200 μl of bacterial suspension containing
1 × 108 CFU of a mixture consisting of four parts
JOL916 (0.8 × 108 CFU) and one part JOL1229 (0.2 × 108
CFU) at 6 and 16 weeks of age. Group II chickens were
primed and boosted with 200 μl of bacterial suspension
containing 2 × 107 CFU of SG 9R at 6 and 16 weeks of
age. Group III chickens were inoculated with 200 μl of
PBS at 6 and 16 weeks of age as the control group. For the
bacteriological examination of eggs, eggs were collected
daily for the four weeks (from 18 to 21 weeks of age)
following the first egg laid by each chicken, and were
Table 1 Immunization, mortality, and gross lesions in the internal organs of chickens after challenge in experiment 1




Prime Booster ENc NFd EN NF
A JOL916/JOL1229 JOL916/JOL1229 10 10* 0.7±1.1* 0.4±1.0* 0.4±1.0* 0.7±0.9*
B JOL916/JOL1229 JOL916 10 10* 0.6±1.0* 0.8±1.1* 0.7±1.2* 0.5±1.0**
C PBS PBS 10 70 2.1±1.4 2.1±1.4 2.1±1.4 2.3±1.3
a JOL916 is a vaccine strain and JOL1229 is an LTB protein-secreting strain for adjuvant. JOL916/JOL1229 is a mixture consisting of 4 parts JOL916 and 1 part
JOL1229. The dose of immunization was 1 × 108 CFU in a volume of 200 μl.
b Gross lesion score (mean ± SEM).
c Enlargement.
d Necrotic foci.
Asterisks indicate a significant difference compared to the control group (*p < 0.05, **p < 0.01). n, numbers of the chickens used.
Jeon et al. BMC Veterinary Research 2013, 9:96 Page 2 of 8
http://www.biomedcentral.com/1746-6148/9/96
examined for SG. Egg production of all hens was moni-
tored for four weeks (from 22 to 25 weeks of age).
Cell-mediated immune response
A lymphocyte proliferation assay (LPA) was performed
in experiment 1 and 2 using specific antigens prepared
from wild-type SG as previously described [8]. Peripheral
blood samples were aseptically collected from five
randomly selected birds per group, for three weeks after
prime and boost immunization. Peripheral blood mono-
nuclear cells (PBMCs) were separated using the
Histopaque®-1077 (Sigma-Aldrich, St. Louis, MO, USA)
according to the product information. Lymphocyte pro-
liferation activity was measured using adenosine triphos-
phate (ATP) bioluminescence as a marker of cell
viability using a ViaLight® Plus (Lonza Rockland, ME,
USA). The blastogenic response of the assay was
expressed as the mean stimulation index (SI), which was
calculated by dividing the mean OD value of the culture
stimulated with the antigen by the mean OD value of
the non-stimulated culture [11].
Humoral immune responses
Indirect enzyme-linked immunosorbent assay (ELISA)
was performed using an outer membrane protein (OMP)
fraction extracted from the wild-type SG strain, JOL420
[8]. Plasma samples were separated by centrifugation of
wing vein peripheral blood to determine plasma im-
munoglobulin G (IgG) concentrations. Intestinal lavage
samples were collected using pilocarpine-based lavage
method [12]. All plasma and intestinal lavage samples
were collected biweekly in experiment 1. In addition, all
plasma and intestinal lavage samples were collected at 0,
3, 8 wppi and 3 wpbi in experiment 2. Evaluation of
plasma IgG and intestinal secretory immunoglobulin A
(sIgA) concentrations was performed as previously de-
scribed [12] using chicken IgG and IgA ELISA Quantita-
tion Kits (Bethyl Laboratories, TX, USA) according to
the product information. Microlon® ELISA plate wells
(Greiner Bio-One GmbH, Frickenhausen, Germany)
were coated with 100 μl of OMP at a concentration of
0.2 mg/ml. Wells were reacted with plasma and intes-
tinal lavage samples at dilutions of 1:250 and 1:100,
respectively, for 1 hr, followed by reaction with HRP-
conjugated goat anti-chicken IgG and IgA at dilutions of
1:100,000 and 1:60,000, respectively, for 1 hr.
Protection efficacy
Chickens in all experiment 1 groups were orally chal-
lenged with 200 μl of bacterial suspension containing
1 × 106 CFU of the wild-type SG strain JOL420, at 4
weeks post-boost-immunization (wpbi). Mortality was
assessed daily for 14 days post challenge. All remaining
animals were euthanized on 14 days post-challenge (dpc)
for postmortem examination. Gross lesions in the livers
and spleens were observed and scored as previously
described [13].
Observation of general condition and body weight after
immunization
In experiment 2, general body condition, clinical symp-
toms, and mortality were observed daily from 6 to 25
weeks of age, for 19 weeks after prime-immunization. In
addition, the body weights of all chickens were recorded
at 5, 9, 13, 17, and 21 weeks of age.
Egg production and bacteriological examination of eggs
after immunization
Eggs were collected daily, and the egg production rate
was measured to assess the influence of immunization
on egg production daily from 22 to 25 weeks of age in
experiment 2. Weekly egg production rates were calcu-
lated as follows: egg production rate = (the total number
of eggs laid)/(the number of hens × 7 days). The bac-
teriological examination of eggs was performed from 18
to 21 weeks of age as previously described, with slight
modification [14,15]. Briefly, eggs of all chickens in each
group were pooled in one batch so that the number of
eggs per batch varied between one and six. Upon collec-
tion, feces on the surfaces of the eggs were removed,
and the eggs were decontaminated by dipping in 95%
ethanol for 1 min. The eggs were broken aseptically, and
the total content of the eggs was pooled and homoge-
nized with sterilized wooden sticks. A volume of 40 ml
of buffered peptone water (BPW) (Becton, Dickinson
and Company, Sparks, MD, USA) per egg was added to
the pooled egg content and incubated at 37°C for 24 hr.
Subsequently, 300 μl of the culture was transferred to
3 ml Rappaport-Vassiliadis R10 (RV) broth (Becton,
Dickinson and Company, Sparks, MD, USA) and incu-
bated at 40°C for 48 hr. A loop of the enriched broth
was streaked onto Brilliant Green Agar (BGA) (Becton,
Dickinson and Company, Sparks, MD, USA), and Salmon-
ella-type colonies were examined after overnight incuba-
tion at 37°C. Positive colonies were confirmed with PCR
using OMPC primers for the Salmonella genus, SG
primers for S. Gallinarum, lon and cpxR primers for the
vaccine strain, and LTB primers for the LTB adjuvant
strain (Table 2) [8,16-18].
Statistical analysis
Statistical analyses were performed with SPSS 16.0 (SPSS
Inc., Chicago, IL, USA). All results are expressed as means ±
standard error of the mean (SEM), unless otherwise speci-
fied. Comparisons between the immunized and control
groups were made using the Mann–Whitney U test.
The chi-square test was performed for significant dif-
ferences of mortality post-challenge between the
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immunized and control groups. Statistical significance
was identified as p-value < 0.05.
Results
General condition and immune responses
No obvious clinical signs were found after oral prime and
boost immunization at 6 and 16 weeks of age, respectively.
There was no evidence of mortality in any of the chickens
after inoculation with the JOL916-JOL1229 mixture or
with JOL916 via oral route. Plasma IgG and intestinal sIgA
concentrations were determined biweekly with indirect
ELISA using specific SG antigen. Antibody responses to
the Salmonella antigen in the plasma and intestinal lavage
samples of the immunized and control chickens are
shown in Figure 1. Plasma IgG concentrations in the
chickens from all immunized groups were significantly
elevated compared to the PBS control group after prime-
and boost-immunization (p < 0.05) (Figure 1A). Intestinal
sIgA concentrations in the chickens from group A were
significantly elevated to 1.6-, 2.0-, and 1.4-fold com-
pared to the control chickens at 3, 5, and 7 weeks post-
prime-immunization (wppi), respectively (p < 0.05). In
group B, intestinal sIgA concentrations were significantly
elevated 1.5- and 1.9-fold compared to the control
chickens at 3 and 5 wppi, respectively (p < 0.05). After
boost immunization, the intestinal sIgA values of the
chickens in group A were 1.9- and 1.8-fold higher com-
pared to the corresponding control group, and the mean
sIgA value of the chickens in group B was 1.8-fold higher
than that of the control group (p < 0.05) (Figure 1B). Cell-
mediated immune responses were examined using a
lymphocyte proliferation response assay (LPA) with spe-
cific antigen extracted from wild-type SG at 3 wppi and 3
wpbi. Lymphocyte proliferation responses to the SG anti-
gen revealed a significant increase in the stimulation indi-
ces (SIs) of all of the immunized groups compared to the
control group (p < 0.05). In addition, the SI value of group
B was approximately 1.4-fold higher than that of Group A
at 3 wpbi (Figure 2).
Protection efficacy against virulent challenge
Chickens from each group were orally challenged with
1 × 106 CFU of virulent wild-type SG JOL420 at 4 wpbi.
Chickens in all immunized groups were markedly
protected against FT (p < 0.05) (Table 1). The mortality
rates in Groups A, B, and C were 10%, 10%, and 70%,
respectively. On 14 dpc, all surviving chickens were
sacrificed for postmortem examination. The control
group demonstrated severe pathological gross lesion
scores of 2.1 ± 1.4, 2.1 ± 1.4, 2.1 ±1.4 and 2.3 ±1.3 for
liver enlargement, liver necrotic foci, spleen enlarge-
ment and spleen necrotic foci, respectively (Table 1).
However, lesion scores in all of the immunized groups
were significantly lower than those of the control group
(p < 0.05 or p < 0.01) (Table 1).
Table 2 Primers used in this study
Primer Primer sequence (5’- 3’) Source
OMPC-F ATCGCTGACTTATGCAATCG Alvarez et al. (2004)
OMPC-R CGGGTTGCGTTATAGGTCTG
SG-F GATCTGCTGCCAGCTCAA Kang et al. (2011)
SG-R GCGCCCTTTTCAAAACATA
lon-both-F ATTTTATCTCCCCTTTCGTTTTTC Jeon et al. (2012)
lon-both-R CTGCCAGCCCTGTTTTTATTAGC
cpxR-both-F CAGCGCCAGCGTCAACCAGAAGAT Jeon et al. (2012)
cpxR-both-R GAGGCCATAACAGCAGCGGTAACT
LTB-F GCTCCCCAGTCTATTACAG Hur and Lee (2011)
LTB-R CTAGTTTTCCATACTGATTG
Figure 1 Antibody responses to the SG mutant JOL916 and the
LTB adjuvant strain JOL1229. Antibody responses to SG specific
antigen in chickens, orally prime-boost immunized with the vaccine
candidate strain (JOL916) and/or the LTB adjuvant strain (JOL1229).
Group A chickens were primed and boosted with a mixture
consisting of four parts JOL916 (0.8 × 108 CFU) and one part
JOL1229 (0.2 × 108 CFU), group B chickens were primed with a
mixture consisting of four parts JOL916 (0.8 × 108 CFU) and one part
JOL1229 (0.2 × 108 CFU), and were boosted with JOL916, and group C
chickens were inoculated with PBS as the control group. (A) Plasma
IgG concentration (μg/ml); (B) Secretory IgA concentration (μg/ml) in
intestinal lavage. Lower case letters indicate a significant difference
(p < 0.05) between each immunized and control group (a: Group A,
b: Group B).
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General condition and body weight increase after
immunization
Oral immunization with the JOL916-JOL1229 mixture or
with SG 9R in the chickens showed no clinical signs such
as anorexia, depression, or diarrhea till the end of the ex-
periment. The weight gains of both the immunized and
negative control groups from 5 to 21 weeks of age are
shown in Figure 3. No significant differences were ob-
served among the groups, and the mean increases at 21
weeks of age were 1587.4 ± 80.3 g, 1673.6 ± 80.4 g, and
1667.6 ± 38.3 g in groups I, II, and III, respectively.
Immune responses induced by the JOL916-JOL1229
mixture compared with those induced by a commercial
vaccine
The cell-mediated immune responses induced by our
mixture vaccine and SG 9R were examined using LPA
on 3 wppi and 3 wpbi. All tested chickens in the immu-
nized groups showed significantly elevated SI values
compared to those in the control group (p < 0.05); SI
values on 3 wppi were 2.6 ± 1.0, 2.1 ± 0.2, and 1.2 ± 0.4
in groups I, II, and III, respectively, and SI values on 3
wpbi were 2.4 ± 0.7, 2.3 ± 0.3, and 1.1 ± 0.1 in groups I,
II, and III, respectively (Table 3). From 3 wppi to 3 wpbi,
plasma IgG concentrations were significantly elevated in
all immunized groups (groups I and II) compared to the
control group (p < 0.01) (Table 3). No significant differ-
ences in SI values or plasma IgG levels were observed
between our mixture group and the SG 9R group during
the experiment. However, intestinal sIgA titers in chick-
ens from group I were 1.9 times higher than those in
control chickens on both 3 wppi and 3 wpbi (p < 0.05),
while the mean increases in intestinal IgA levels in
group II were not statistically significant compared to
the control group (Table 3).
Egg production after immunization
In experiment 2, the egg production rate of the immunized
groups was observed from 22 to 25 weeks of age. The aver-
age overall egg production rate was 91.7% for chickens im-
munized with our strains, 92.5% for those immunized with
SG 9R, and 93.1% for unimmunized chickens; there were
no significant differences in the number of eggs laid by im-
munized hens (Table 4).
Isolation of the vaccine strain from egg contents after
immunization
In experiment 2, eggs from the immunized chickens
with our vaccine strains were collected daily from 18 to
21 weeks of age, and examined for detection of Salmon-
ella. Over the four weeks of the experiment, our vaccine
strains were not detected in any eggs from the immu-
nized chickens.
Figure 2 Antigen-specific T lymphocyte proliferation to
Salmonella Gallinarum. Antigen-specific proliferation of
lymphocytes from peripheral blood in chickens, orally prime-boost
immunized with the vaccine candidate strain (JOL916) and/or the
LTB adjuvant strain (JOL1229) using soluble antigen from the wild-
type SG. Groups A to C are referred to in Figure 1. Asterisks indicate
a significant difference between each immunized and control group
(p < 0.05). wppi = week post-prime-immunization; wpbi = week
post-boost-immunization.
Figure 3 Body weight increase in chickens immunized with the
JOL916-JOL1229 mixture and SG 9R. Body weight increase in
group I to III; group I chickens were orally primed and boosted with
1 × 108 CFU of the mixture consisting of four part JOL916 (0.8 × 108
CFU) and one part JOL1229 (0.2 × 108 CFU) at 6 and 16 weeks of
age, group II chickens were subcutaneously primed and boosted
with 2 × 107 CFU of SG 9R at 6 and 16 weeks of age, group III
chickens were inoculated with PBS at 6 and 16 weeks of age as the
control group.
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Discussion
The prime-boost immunization strategy can elicit long-
lasting humoral, mucosal, and cellular responses against
a variety of antigens [19]. In the present study, we evalu-
ated protection efficacy and immune responses in layer
chickens, which had been immunized with a double
immunization in order to optimize the efficacy of the
vaccine. In the first experiment, group A chickens were
primed and boosted with a mixture consisting of
JOL916 and JOL1229, and group B chickens were
primed with the same mixture and boosted with JOL916
alone. Both immunized groups showed a significant in-
crease in the intestinal sIgA levels after prime and boost
immunization, and this result indicates that the oral im-
munizations can stimulate antigen-specific mucosal im-
munity (p < 0.05) (Figure 1B). The mucosal immune
defense is largely mediated by sIgA antibodies, which are
the first line of defense against microorganisms and op-
erate through immune exclusion [20,21]. Mucosal im-
munizations such as oral inoculations can be an effective
means of inducing sIgA, as well as systemic antibodies
and cell-mediated immune responses [22]. Plasma IgG
antibody levels in the immunized groups were also sig-
nificantly increased compared to those in the control
group (p < 0.05) (Figure 1A). Systemic antibodies clear
Salmonella from the blood, and also promote phagocyt-
osis of Salmonella by opsonization method [23,24]. Sig-
nificant cell-mediated immune responses were shown by
LPA in both immunized groups compared to the control
group at 3 wppi and 3 wpbi (p < 0.05) (Figure 2). It is
widely accepted that enhancement of cellular immunity
is crucial for protection against a primary Salmonella in-
fection [25]. In addition, Th1-dominated cell-mediated
responses are likely to be more important in the clear-
ance of SG, which is believed to survive and multiply
within macrophages [3,26]. All immunological data indi-
cate that oral immunization with the LTB strain with a
prime-boost strategy can effectively enhance and extend
considerable levels of acquired immunity, including the
mucosal immune responses.
Generally, oral tolerance has been defined as the spe-
cific suppression of cell-mediated and/or humoral im-
mune responses to antigens by prior oral administration
of the antigen [27]. Oral administration of antigens with
recombinant enterotoxin B subunits such as LTB and
cholera toxin B subunit (CTB) has been found to induce
tolerance to the same antigens when subsequently inoc-
ulated [28]. In the experiment 1, chickens in groups A
and B were both orally inoculated with a JOL916-
JOL1229 mixture at 6 weeks of age. Group A chickens
were orally boosted with the same mixture, while group
B chickens were orally boosted with JOL916 alone at 16
weeks of age. Prime and boost immunizations offered
significant protection efficacy against a wild-type SG
challenge (p < 0.05), while 70% mortality was observed
in the unimmunized control group (Table 1). In
addition, the gross lesion scores of internal organs in the
immunized groups were significantly lower than those of
the control group (p < 0.05) (Table 1). Very mild or no
gross lesions in the liver and spleen in the immunized
groups may indicate that the acquired immunity suc-
cessfully controlled FT infection after the booster inocu-
lation. In addition, there were no statistically significant
differences in the protection efficacy or immune re-
sponses between groups A and B (Figures 1 and 2, and
Table 2), which suggests that oral tolerance may not be
induced by boost inoculation with the LTB adjuvant
strain. It is possible that the time interval (10 weeks) be-
tween the prime and boost inoculations can be a factor
in the evasion of an oral tolerance event.
In the experiment 2, we compared the immunogen-
icity, body weight, and egg production rates of the chick-
ens immunized with the JOL916-JOL1229 mixture to
Table 3 SG-antigen-specific immune responses after prime -boost immunization in experiment 2
Group n LPA Plasma IgG (μg/ml) Intestinal sIgA (μg/ml)
3 wppi 3 wpbi 0 wppi 3 wppi 8 wppi 3 wpbi 0 wppi 3 wppi 8 wppi 3 wpbi
I 5 2.6±1.0* 2.4±0.7* 73.8±32.9 182.9±9.9** 138.5±12.2** 174.6±29.5** 4.3±0.6 9.3±0.8* 5.5±0.7 8.9±1.3*
II 5 2.1±0.2* 2.3±0.3* 75.7±43.9 171.7±23.2** 132.2±5.2** 177.8±14.0** 4.0±0.2 5.5±0.3 5.7±0.3 6.5±0.6
III 5 1.2±0.4 1.1±0.1 41.4±11.5 40.1±18.3 30.5±12.1 36.5±17.7 4.5±0.6 4.8±0.2 4.3±0.1 4.6±0.4
Group I chickens were primed and boosted with a JOL916-JOL1229 mixture, group II chickens were primed and boosted with SG9R, and group III chickens were
inoculated with PBS as a control. LPA, lymphocyte proliferation assay. wppi, week post-prime-immunization. wpbi, week post-boost-immunization. Values
represent stimulation index mean ± SEM. Asterisks indicate a significant difference compared to the control group (*p < 0.05, **p < 0.01). n, numbers of the
chickens used.
Table 4 Egg production rate in the immunized and
unimmunized groups in experiment 2
Group Week of age Averages
22 23 24 25
I 90.0a 93.7 91.7 91.7 91.7
II 91.4 92.9 90.5 95.3 92.5
III 90.0 95.7 94.3 92.5 93.1
Group I chickens were primed and boosted with a JOL916-JOL1229 mixture,
group II chickens were primed and boosted with SG9R, and group III chickens
were inoculated with PBS as a control.
aValues represent the percentages of egg production calculated as described
in the section of methods.
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those immunized with SG 9R, a commercial SG vac-
cine. The cell-mediated immune responses and the sys-
temic IgG responses were significantly increased in
both immunized groups compared to the control group
(p < 0.05 or p < 0.01) (Table 3). However, the sIgA con-
centrations of the chickens immunized with SG 9R
were not significantly elevated compared to the control
group (Table 3), while a significant elevation in intes-
tinal sIgA in chickens immunized with our mixture was
observed at 3 wppi and 3 wpbi (p < 0.05). The body
weights of all immunized chickens were monitored for
16 weeks (5 to 21 weeks of age) after vaccination. There
were no significant differences in body weight gain
among the groups (Figure 3). The egg production rate
after vaccination was also examined in the immunized
groups and control group for four weeks (22 to 25
weeks of age). There was no statistical difference in
number of eggs laid by the double immunized chickens
with our vaccine mixture, with SG 9R strain, and the
unimmunized chickens (Table 4). These data suggest
that both immunized groups showed similar results in
the body weight gain, egg production rates and sys-
temic IgG immune response. However, immunization
with only JOL916-JOL1229 mixture showed enhanced
intestinal sIgA immune response, which may be im-
portant to mediate antibody-dependent T-cell-mediated
cytotoxicity against Salmonella [29].
In FT infection, chickens may infect their own, as well
as succeeding generations through egg transmission [2].
In the present study, bacteriological examination of the
total content of the eggs was performed to determine the
safety of the JOL916-JOL1229 mixture. The SG mutant
and/or LTB adjuvant strains were not detected in any egg
of the immunized chickens during four weeks (18 to 21
weeks of age), which suggests that immunization with the
JOL916-JOL1229 mixture does not cause bacterial con-
tamination of the ovum.
Conclusion
In conclusion, data from both the experiments indicate that
the immunizations with the JOL916-JOL1229 can be safe;
and can induce acquired immunity including enhanced
mucosal immunity. Furthermore, double immunization
with the JOL916-JOL1229 may trigger elevated levels of im-
mune responses to optimize the protection efficacy against
FT infection in hens.
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